anonymous
Guest
anonymous
Guest
Thanks Dez for the new “pay for performance” bonus structure! For IC 3 if you aren’t 80% to goal you are paid ZERO bonus. That would be fine if the goals were reasonable or somewhat attainable- but most goals were an increase of 230% or more over baseline!!!! A baseline skewed by Free Trial Offers - no less. Therefore NO ONE is even close to 80% to goal which only equates to a 50% payout by the way. This is such crap bc the company is touting amazing sales to the shareholders but will not be paying their sales reps that are working harder than ever to sell this drug. This is a tough, tough sale and if Novartis isn’t going to recognize that and “make it right” with bonuses they will continue to lose their top talent in CV. No one is expecting to be paid a ton just a fair bonus that equates to the amount of work this drug requires- the company is making their $$ time to pay the people that are in the trenches. It’s bad enough that PSS colleagues are being paid more than sales reps and they generate ZERO business for the company. If it weren’t for sales PSS would have nothing to do. This whole thing is so back asswards it’s absurd. This drug has no chance if they continue down this path- new senior leadership is required immediately to save it and that’s not looking likely to happen at all.